Abstract
Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. In recent years increasing evidence supports the pharmaceutical potential of curcumin, a polyphenolic compound in the spice turmeric, against PD. Here we briefly summarize the pharmacological activities of curcumin in vitro and in animal models of PD, including counteracting oxidative stress and inflammation, preventing α-synuclein aggregation and fibrillation, and inhibiting monoamine oxidase B, which endow curcumin with multiple pharmaceutical activities against PD and encourage further studies to investigate its clinical effects.
Keywords: Parkinson's disease, curcumin, antioxidant, anti-inflammation, anti-aggregation.
CNS & Neurological Disorders - Drug Targets
Title:The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
Volume: 13 Issue: 2
Author(s): Hong-Fang Ji and Liang Shen
Affiliation:
Keywords: Parkinson's disease, curcumin, antioxidant, anti-inflammation, anti-aggregation.
Abstract: Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. In recent years increasing evidence supports the pharmaceutical potential of curcumin, a polyphenolic compound in the spice turmeric, against PD. Here we briefly summarize the pharmacological activities of curcumin in vitro and in animal models of PD, including counteracting oxidative stress and inflammation, preventing α-synuclein aggregation and fibrillation, and inhibiting monoamine oxidase B, which endow curcumin with multiple pharmaceutical activities against PD and encourage further studies to investigate its clinical effects.
Export Options
About this article
Cite this article as:
Ji Hong-Fang and Shen Liang, The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (2) . https://dx.doi.org/10.2174/18715273113129990077
DOI https://dx.doi.org/10.2174/18715273113129990077 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Connexin Genes as Promising Therapeutic Targets in Cancers
Current Pharmacogenomics Extracellular Citrate in Health and Disease
Current Molecular Medicine Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry